140 related articles for article (PubMed ID: 34045227)
1. Harnessing the hERG1/β1 Integrin Complex via a Novel Bispecific Single-chain Antibody: An Effective Strategy against Solid Cancers.
Duranti C; Iorio J; Lottini T; Lastraioli E; Crescioli S; Bagni G; Lulli M; Capitani C; Bouazzi R; Stefanini M; Carraresi L; Iamele L; De Jonge H; Arcangeli A
Mol Cancer Ther; 2021 Aug; 20(8):1338-1349. PubMed ID: 34045227
[TBL] [Abstract][Full Text] [Related]
2. Cardiac safety assessment of a novel recombinant bispecific antibody targeting the ether-à-go-go related gene 1 (hERG1)-β1 integrin macromolecular complex.
Santini L; Duranti C; Palandri C; Giammarino L; Musumeci M; Carlucci L; Capitani C; Colasurdo R; Recchia F; Cerbai E; Coppini R; Arcangeli A
Front Pharmacol; 2023; 14():1237431. PubMed ID: 37767396
[No Abstract] [Full Text] [Related]
3. Targeting the hERG1 and β1 integrin complex for cancer treatment.
Arcangeli A; Iorio J; Duranti C
Expert Opin Ther Targets; 2024 Mar; 28(3):145-157. PubMed ID: 38372580
[TBL] [Abstract][Full Text] [Related]
4. The conformational state of hERG1 channels determines integrin association, downstream signaling, and cancer progression.
Becchetti A; Crescioli S; Zanieri F; Petroni G; Mercatelli R; Coppola S; Gasparoli L; D'Amico M; Pillozzi S; Crociani O; Stefanini M; Fiore A; Carraresi L; Morello V; Manoli S; Brizzi MF; Ricci D; Rinaldi M; Masi A; Schmidt T; Quercioli F; Defilippi P; Arcangeli A
Sci Signal; 2017 Apr; 10(473):. PubMed ID: 28377405
[TBL] [Abstract][Full Text] [Related]
5. Combination Therapy with a Bispecific Antibody Targeting the hERG1/β1 Integrin Complex and Gemcitabine in Pancreatic Ductal Adenocarcinoma.
Lottini T; Duranti C; Iorio J; Martinelli M; Colasurdo R; D'Alessandro FN; Buonamici M; Coppola S; Devescovi V; La Vaccara V; Coppola A; Coppola R; Lastraioli E; Arcangeli A
Cancers (Basel); 2023 Mar; 15(7):. PubMed ID: 37046674
[TBL] [Abstract][Full Text] [Related]
6. hERG1 channels modulate integrin signaling to trigger angiogenesis and tumor progression in colorectal cancer.
Crociani O; Zanieri F; Pillozzi S; Lastraioli E; Stefanini M; Fiore A; Fortunato A; D'Amico M; Masselli M; De Lorenzo E; Gasparoli L; Chiu M; Bussolati O; Becchetti A; Arcangeli A
Sci Rep; 2013 Nov; 3():3308. PubMed ID: 24270902
[TBL] [Abstract][Full Text] [Related]
7. VEGFR-1 (FLT-1), beta1 integrin, and hERG K+ channel for a macromolecular signaling complex in acute myeloid leukemia: role in cell migration and clinical outcome.
Pillozzi S; Brizzi MF; Bernabei PA; Bartolozzi B; Caporale R; Basile V; Boddi V; Pegoraro L; Becchetti A; Arcangeli A
Blood; 2007 Aug; 110(4):1238-50. PubMed ID: 17420287
[TBL] [Abstract][Full Text] [Related]
8. Physical and functional interaction between integrins and hERG1 channels in cancer cells.
Pillozzi S; Arcangeli A
Adv Exp Med Biol; 2010; 674():55-67. PubMed ID: 20549940
[TBL] [Abstract][Full Text] [Related]
9. Rearranging the domain order of a diabody-based IgG-like bispecific antibody enhances its antitumor activity and improves its degradation resistance and pharmacokinetics.
Asano R; Shimomura I; Konno S; Ito A; Masakari Y; Orimo R; Taki S; Arai K; Ogata H; Okada M; Furumoto S; Onitsuka M; Omasa T; Hayashi H; Katayose Y; Unno M; Kudo T; Umetsu M; Kumagai I
MAbs; 2014; 6(5):1243-54. PubMed ID: 25517309
[TBL] [Abstract][Full Text] [Related]
10. Integrins regulate hERG1 dynamics by girdin-dependent Gαi3: signaling and modeling in cancer cells.
Duranti C; Iorio J; Bagni G; Chioccioli Altadonna G; Fillion T; Lulli M; D'Alessandro FN; Montalbano A; Lastraioli E; Fanelli D; Coppola S; Schmidt T; Piazza F; Becchetti A; Arcangeli A
Life Sci Alliance; 2024 Jan; 7(1):. PubMed ID: 37923359
[TBL] [Abstract][Full Text] [Related]
11. Chemotherapy resistance in acute lymphoblastic leukemia requires hERG1 channels and is overcome by hERG1 blockers.
Pillozzi S; Masselli M; De Lorenzo E; Accordi B; Cilia E; Crociani O; Amedei A; Veltroni M; D'Amico M; Basso G; Becchetti A; Campana D; Arcangeli A
Blood; 2011 Jan; 117(3):902-14. PubMed ID: 21048156
[TBL] [Abstract][Full Text] [Related]
12. Expression and purification of a novel single-chain diabody (scDb-hERG1/β1) from Pichia pastoris transformants.
Duranti C; Lastraioli E; Iorio J; Capitani C; Carraresi L; Gonnelli L; Arcangeli A
Protein Expr Purif; 2021 Aug; 184():105879. PubMed ID: 33826963
[TBL] [Abstract][Full Text] [Related]
13. The role of potassium channels in tumours of the gastrointestinal tract: a focus on the human ether-à-go-go related gene 1 channels.
Arcangeli A; Duranti C; Iorio J; Lastraioli E
J Physiol; 2023 May; 601(9):1597-1610. PubMed ID: 36215066
[TBL] [Abstract][Full Text] [Related]
14. Prognostic role of hERG1 Potassium Channels in Neuroendocrine Tumours of the Ileum and Pancreas.
Iorio J; Antonuzzo L; Scarpi E; D'Amico M; Duranti C; Messerini L; Sparano C; Caputo D; Lavacchi D; Borzomati D; Antonelli A; Nibid L; Perrone G; Coppola A; Coppola R; di Costanzo F; Lastraioli E; Arcangeli A
Int J Mol Sci; 2022 Sep; 23(18):. PubMed ID: 36142530
[TBL] [Abstract][Full Text] [Related]
15. hERG1 channels drive tumour malignancy and may serve as prognostic factor in pancreatic ductal adenocarcinoma.
Lastraioli E; Perrone G; Sette A; Fiore A; Crociani O; Manoli S; D'Amico M; Masselli M; Iorio J; Callea M; Borzomati D; Nappo G; Bartolozzi F; Santini D; Bencini L; Farsi M; Boni L; Di Costanzo F; Schwab A; Onetti Muda A; Coppola R; Arcangeli A
Br J Cancer; 2015 Mar; 112(6):1076-87. PubMed ID: 25719829
[TBL] [Abstract][Full Text] [Related]
16. HERG1 functions as an oncogene in pancreatic cancer and is downregulated by miR-96.
Feng J; Yu J; Pan X; Li Z; Chen Z; Zhang W; Wang B; Yang L; Xu H; Zhang G; Xu Z
Oncotarget; 2014 Jul; 5(14):5832-44. PubMed ID: 25071021
[TBL] [Abstract][Full Text] [Related]
17. Biodistribution of a bispecific single-chain diabody and its half-life extended derivatives.
Stork R; Campigna E; Robert B; Müller D; Kontermann RE
J Biol Chem; 2009 Sep; 284(38):25612-9. PubMed ID: 19628871
[TBL] [Abstract][Full Text] [Related]
18. Human ether-a-go-go-related gene 1 channels are physically linked to beta1 integrins and modulate adhesion-dependent signaling.
Cherubini A; Hofmann G; Pillozzi S; Guasti L; Crociani O; Cilia E; Di Stefano P; Degani S; Balzi M; Olivotto M; Wanke E; Becchetti A; Defilippi P; Wymore R; Arcangeli A
Mol Biol Cell; 2005 Jun; 16(6):2972-83. PubMed ID: 15800067
[TBL] [Abstract][Full Text] [Related]
19. HERG1 promotes esophageal squamous cell carcinoma growth and metastasis through TXNDC5 by activating the PI3K/AKT pathway.
Wang H; Yang X; Guo Y; Shui L; Li S; Bai Y; Liu Y; Zeng M; Xia J
J Exp Clin Cancer Res; 2019 Jul; 38(1):324. PubMed ID: 31331361
[TBL] [Abstract][Full Text] [Related]
20. A T-cell-engaging B7-H4/CD3-bispecific Fab-scFv Antibody Targets Human Breast Cancer.
Iizuka A; Nonomura C; Ashizawa T; Kondou R; Ohshima K; Sugino T; Mitsuya K; Hayashi N; Nakasu Y; Maruyama K; Yamaguchi K; Akiyama Y
Clin Cancer Res; 2019 May; 25(9):2925-2934. PubMed ID: 30737243
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
